Get the Stockscreener App
2.57
8.44%
0.20
After Hours:
2.57
Cabaletta Bio Inc stock is traded at $2.57, with a volume of 2.61M.
It is up +8.44% in the last 24 hours and down -6.20% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$2.37
Open:
$2.38
24h Volume:
2.61M
Relative Volume:
0.66
Market Cap:
$247.40M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-1.5482
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
+23.56%
1M Performance:
-6.20%
6M Performance:
+37.43%
1Y Performance:
-14.62%
1-Day Range:
$2.34
$2.69
1-Week Range:
$2.07
$2.69
52-Week Range:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.57 | 228.15M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio to Present at Key Global Healthcare and Immunology Conferences - MSN
How supply chain issues affect Cabaletta Bio Inc. stock2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Can Cabaletta Bio Inc. stock maintain operating margins2025 Market Overview & Free Real-Time Volume Trigger Notifications - newser.com
Will Cabaletta Bio Inc. stock outperform Nasdaq indexQuarterly Profit Review & High Accuracy Buy Signal Tips - newser.com
How Cabaletta Bio Inc. stock reacts to oil pricesJuly 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
How Cabaletta Bio Inc. stock performs in rising dollar environmentTrade Risk Assessment & Weekly High Momentum Picks - newser.com
CABALETTA BIO INC (CABA.MX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Cabaletta Bio Inc. stock could rally in 2025Bond Market & AI Based Buy/Sell Signal Reports - newser.com
Cabaletta Bio’s Bold Autoimmune Push Raises Big Questions About the Future of CAR T - MyChesCo
Tools to assess Cabaletta Bio Inc.’s risk profileJuly 2025 WrapUp & Precise Entry and Exit Recommendations - newser.com
Is Cabaletta Bio Inc. stock attractive for ETFsLong Setup & Weekly Return Optimization Plans - newser.com
Will Cabaletta Bio Inc. see short term momentumLong Setup & Real-Time Stock Entry Alerts - newser.com
How Cabaletta Bio Inc. stock reacts to bond yieldsChart Signals & Verified Short-Term Plans - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsRate Cut & Fast Entry High Yield Tips - newser.com
What technical signals suggest for Cabaletta Bio Inc. stock2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
Is Cabaletta Bio Inc. stock a contrarian buy2025 Trading Volume Trends & Safe Capital Investment Plans - Fundação Cultural do Pará
Cabaletta Bio Advances in Autoimmune Therapy Development - MSN
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.July 2025 Reactions & High Accuracy Trade Signal Alerts - newser.com
Cabaletta Bio (CABA) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cabaletta Bio Draws Analyst Praise Despite Growing Losses - Finimize
Cabaletta Bio Reports Breakthrough Results in Autoimmune Disease Trials - MSN
Cabaletta Bio (CABA) Q3 Earnings Beat Expectations - GuruFocus
Cabaletta (CABA) Advances Clinical Program with Promising Results - GuruFocus
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):